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Abstract
Background: The mortality rate of severely ill patients treated with venoarterial extracorporeal membrane
oxygenation (VA-ECMO) remains unknown because of differences in patient background, clinical settings, and
sample sizes between studies. We determined the in-hospital mortality of VA-ECMO patients and the proportion
weaned from VA-ECMO using a national inpatient database in Japan.
Methods: Patients aged ≥19 years who received VA-ECMO during hospitalization for cardiogenic shock, pulmonary
embolism, hypothermia, poisoning, or trauma between 1 July 2010 and 31 March 2013 were identified, using The
Japanese Diagnosis Procedure Combination national inpatient database.
Results: The primary outcome was in-hospital mortality and the secondary outcome was the proportion weaned
from VA-ECMO. A total of 5263 patients received VA-ECMO during the study period. The majority of patients had
cardiogenic shock (n = 4,658). The number of patients weaned from VA-ECMO was 3389 (64.4 %) and in-hospital
mortality after weaning from VA-ECMO was 1994 (37.9 %). In-hospital mortality without cardiac arrest in the cardiogenic
shock group was significantly lower than that in patients with cardiac arrest (70.5 % vs. 77.1 %, p <0.001). In the
multivariable logistic regression including multiple imputation, higher age and greater or smaller body mass index were
significantly associated with in-hospital mortality, whereas hospital volume was not associated with such mortality.
Conclusions: The present nationwide study showed high mortality rates in patients who received VA-ECMO, and in
particular in patients with cardiogenic shock and in patients with cardiac arrest. Weaning from VA-ECMO did not
necessarily result in survival. Further studies are warranted to clarify risk-adjusted mortality of VA-ECMO using more
detailed data on patient background.
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Background
Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) is one of the life-supporting procedures
that may be given to critically ill patients with refractory
cardiogenic shock, pulmonary embolism, hypothermia,
or drug poisoning [1, 2]. VA-ECMO can be used tem-
porarily in critically ill patients until intensive therapies
for underlying diseases take effect. Thus, VA-ECMO is
considered to be a last resort to save life.
The reported mortality of patients with refractory car-
diogenic shock treated with VA-ECMO varies widely
(24–64 %), and may be related to differences in patient
background and clinical settings. Previous studies of VA-
ECMO have also been limited because of the small sam-
ple sizes (15–202 patients) [3–14]. The Extracorporeal
Life Support Organization (ELSO) Guidelines for Adult
Cardiac Failure state that the estimated proportion of
patients surviving to discharge after VA-ECMO for
cardiogenic shock is 40 % [15]. However, there are
few data on the effectiveness of VA-ECMO for dis-
eases or conditions other than cardiogenic shock.
Hypothermia is the second most frequent disorder for
which VA-ECMO is used, but the sample sizes of pre-
vious hypothermia studies (n = 24–68) [16–19] were
smaller than those of cardiogenic shock studies. To
date, the indication for, mortality in, or successful
weaning from, VA-ECMO remains unknown for dis-
eases or conditions other than cardiogenic shock.
The aims of this study were to investigate the in-
hospital mortality of patients receiving VA-ECMO and
the proportions of patients weaned from VA-ECMO,
using data from a national inpatient database in Japan.
Methods
This study was approved by the Institutional Review
Board of The University of Tokyo. The requirement for
informed patient consent was waived because of the an-
onymous nature of the data.
Data source
The Japanese Diagnosis Procedure Combination (DPC)
database includes administrative claims and discharge
abstract data for all inpatients discharged from more
than 1000 participating hospitals nationwide. It covers
approximately 92 % (244/266) of all tertiary-care
emergency hospitals in Japan. The database includes
the following patient information: age; sex; body weight
and height; primary diagnosis; comorbidities on admis-
sion; post-admission complications classified according
to the International Classification of Diseases 10th Re-
vision (ICD-10) codes; medical procedures designated
using original Japanese codes, including VA-ECMO,
intra-aortic balloon pumping (IABP), pulmonary ar-
tery catheterization, and continuous renal replacement
therapy; daily records of drug administration and devices
used; length of stay; and discharge status. The dates of
hospital admission, surgery, bedside procedures, drugs
administered and hospital discharge are recorded using a
uniform data submission form. This study used data from
1 July 2010 to 31 March 2013.
Patient selection
We included patients aged ≥19 years who received
VA-ECMO during hospitalization. We selected patients
who were diagnosed at admission as having cardiogenic
shock (ICD-10 codes, I05, I07, I08, I20-22, I33-35, I40-42,
I46, and I49-51), pulmonary embolism (I26), hypothermia
(T68), poisoning (T36-65), or trauma (S$ and T0). We ex-
cluded patients with acute respiratory distress syndrome.
Variables and outcomes
Baseline variables included age, sex and body mass index
(BMI). Patients with cardiogenic shock were categorized
in four age groups: 19–39, 40–59, 60–79 and ≥80 years.
BMI was categorized as being underweight (BMI
<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), or over-
weight (≥25.0 kg/m2). Patients were also divided into
those who had or who had not had an episode of cardiac
arrest. Hospital volume was defined as the number of
patients receiving VA-ECMO per year at each hospital.
Hospital volume was categorized in tertiles and so the
number of patients in each category was almost equal.
Myocarditis, chronic renal failure, liver failure, and cen-
tral nervous system dysfunction were extracted based on
ICD-10 codes. The primary outcome was in-hospital
mortality. The secondary outcome was the proportion of
patients weaned from VA-ECMO.
Statistical analysis
Data are presented as percentages and numbers, or
means and standard deviations. The chi-square test and
Fisher’s exact test were performed to compare propor-
tions in the different groups. In the cardiogenic shock
group, we performed multivariable logistic regression
analysis to examine the association of in-hospital mortal-
ity with various factors, including several components of
the survival after venoarterial ECMO (SAVE) score for
VA-ECMO (age, sex, weight, myocarditis (ICD-10 codes,
I40-41), pre-ECMO cardiac arrest, pre-ECMO chronic
renal failure (N18), liver failure pre-ECMO (K70-77),
pre-ECMO central nervous system dysfunction (G09-11,
G20-21, G23, G31-32, G35-37, G40-41, G45-46, G80-81,
S06), and duration of intubation prior to VA-ECMO) [20],
hospital volume, IABP, pulmonary artery catheterization,
and continuous renal replacement therapy, while also
adjusting for within-hospital clustering using a generalized
estimating equation [21]. We performed multiple im-
putation to replace each missing value with a set of
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substituted plausible values by creating 20 filled-in
complete datasets using a Markov chain Monte Carlo
algorithm known as “chained equations imputation,”
because there were some missing values for BMI and
duration of intubation prior to VA-ECMO [22]. Multiple
imputation assumes that data are missing at random and
that any systematic differences between the missing and
observed values can be explained by differences in the
observed data [23]. A p value <0.05 was considered statis-
tically significant. All statistical analyses were performed
using IBM SPSS version 22.0 (IBM Corp., Armonk,
NY, USA).
Results
We identified a total of 5263 patients who received
VA-ECMO during the study period. The background
characteristics of the patients are presented in Table 1.
The largest number of patients was in the cardiogenic
shock group (n = 4658). The proportion of male pa-
tients in the pulmonary embolism group was smaller
than that in the cardiogenic shock group. The mean
age ranged from 45.9–68.7 years. In-hospital mortality
ranged from 62.0–73.6 %.
Table 2 shows in-hospital mortality and the proportion
of patients weaned from VA-ECMO in each of the five
etiological categories. Overall, 34.6 % of all patients died
during VA-ECMO, 37.9 % died after weaning from
VA-ECMO, and 26.5 % were discharged from hospital
after weaning from ECMO.
Table 3 shows in-hospital death and the proportion of
patients weaned from VA-ECMO in each of the seven
underlying diseases in the cardiogenic shock group. The
proportion discharged from hospital after weaning from
ECMO was significantly larger in patients with heart
failure (31.1 %, p < 0.001) and in patients with myocardi-
tis (41.9 %, p < 0.001) than in patients with ischemic
heart disease (20.3 %). The causes of death after weaning
from VA-ECMO in the cardiogenic shock group were:
heart failure (n = 580, 30.9 %); infection (n = 169, 9.0 %);
hemorrhage (n = 135, 7.2 %); cerebrovascular events
(n = 79, 4.2 %); respiratory failure (n = 76, 4.1 %); multiple
organ failure (n = 248, 13.2 %); and other (n = 211, 11.3 %).
Data on the cause of death were missing for 377 of these
patients (20.1). The types of anticoagulant used in the car-
diogenic shock group were: heparin (n = 3794, 81.5 %);
dalteparin (n = 32, 0.7 %); and argatroban (n = 35, 0.8 %).
Data were missing for 797 of these patients (17.1 %). The
incidence of hemorrhage was 21.3 % (n = 808) with
heparin, 40.6 % (n = 13) with dalteparin, and 22.9 %
(n = 8) with argatroban. Two patients also received
left ventricular assistance. The numbers of patients
who received VA-ECMO within 1, 2, 3–7 and ≥8 days
of hospitalization were 2904 (62.3 %), 228 (4.9 %),
589 (12.6 %), and 937 (20.1 %), respectively.
Table 4 shows the in-hospital mortality of patients in
the cardiogenic shock group, who had or had not had
cardiac arrest, according to the seven underlying cardiac
diseases. In-hospital mortality in patients with cardiac
Table 1 Patient background (n = 5263)
Cardiogenic shock (n = 4658) Pulmonary embolism (n = 353) Hypothermia (n = 99) Poisoning (n = 50) Trauma (n = 103)
Sex
Male, n (%) 3399 (73.0) 131 (37.1) 63 (63.6) 24 (48.0) 73 (70.9)
Age, mean (SD) 64.8 (13.7) 60.6 (15.6) 68.7 (15.2) 45.9 (18.1) 56.4 (20.8)
Death, n (%) 3429 (73.6) 226 (64.0) 65 (65.7) 31 (62.0) 66 (64.1)
SD standard deviation
Table 2 In-hospital death and weaning from VA-ECMO among patients classified by six etiological categories










All, n (%) 5263 3817 (72.5) 1823 (34.6) 51 (1.0) 1395 (26.5) 1994 (37.9)
Cardiogenic shock, n (%) 4658 3429 (73.6) 1554 (33.4) 44 (0.9) 1185 (25.4) 1875 (40.3)
Pulmonary embolism, n (%)* 353 226 (64.0) 151 (42.8) 7 (2.0) 120 (34.0) 75 (21.2)
Hypothermia, n (%)* 99 65 (65.7) 49 (49.5) 0 (0.0) 34 (34.3) 16 (16.2)
Poisoning, n (%)** 50 31 (62.0) 22 (44.0) 0 (0.0) 19 (38.0) 9 (18.0)
Trauma, n (%)* 103 66 (64.1) 47 (45.6) 0 (0.0) 37 (35.9) 19 (18.4)
*p < 0.001 for in-hospital death after weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) vs. cardiogenic shock
**p < 0.05 for in-hospital death after weaning from VA-ECMO vs. cardiogenic shock
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arrest ranged from 60.9–100 % and in patients without
cardiac arrest it ranged from 54.9 %–77.0 % (p < 0.001).
In-hospital mortality was significantly lower in patients
who had not had cardiac arrest than in those who had
had cardiac arrest for those with cardiogenic shock,
heart failure and cardiomyopathy (70.5 % vs. 77.1 %,
p < 0.001; 64.9 % vs. 71.7 %, p < 0.05; and 61.0 % vs.
81.0 %, p < 0.05, respectively).
Table 5 presents the in-hospital mortality in each cat-
egory of patients undergoing VA-ECMO for cardiogenic
shock. Sex was not significantly associated with mortal-
ity. No significant differences in in-hospital mortality
were observed between the hospital volume categories.
Table 6 shows the results of the multivariable logistic
regression analysis for in-hospital mortality, including
multiple imputation. Higher age, and greater or smaller
BMI were significantly associated with higher mortality.
Hospital volume was not significantly associated with
mortality.
Discussion
The present study investigated the indication for, mortal-
ity in, and rate of successful weaning from VA-ECMO,
using a Japanese national DPC inpatient database. The
majority of patients receiving VA-ECMO had cardio-
genic shock (88.5 %). In-hospital mortality was about
65 % for all underlying diseases, and the rate of weaning
from VA-ECMO was about 65 %. The advantage of this
study was its much larger sample size than was used in
previous studies. The present study clarified the practice
patterns in the use of VA-ECMO in a nationwide clinical
setting. Although there is no evidence on the effective-
ness of VA-ECMO for trauma patients, our results
showed that VA-ECMO was used for some trauma pa-
tients in real-world clinical practice. The present study
demonstrated significantly lower mortality in the trauma
group compared with the cardiogenic shock group. This
may be because patients in the trauma group were rela-
tively younger and had fewer chronic diseases.
In this study we observed the in-hospital mortality
under VA-ECMO and weaning from VA-ECMO accord-
ing to each disease or condition. Mortality during VA-
ECMO was 34.6 %, the overall rate of discharge was
about 30 %, and in-hospital mortality after weaning from
VA-ECMO was about 40 %. About half of patients
weaned from VA-ECMO died in hospital. This high pro-
portion may be partly explained by the persisting severe
condition of the patients after weaning from VA-ECMO.
Table 3 In-hospital death and weaning from VA-ECMO among patients in the cardiogenic shock group










Ischemic heart disease, n (%) 1968 1556 (79.1) 725 (36.8) 12 (0.6) 400 (20.3) 831 (42.2)
Heart failure, n (%)* 1621 1099 (67.8) 488 (30.1) 18 (1.1) 504 (31.1) 611 (37.7)
Valvular disease, n (%) 640 493 (77.0) 246 (38.4) 5 (0.8) 142 (22.2) 247 (38.6)
Myocarditis, n (%)* 186 106 (57.0) 24 (12.9) 2 (1.1) 78 (41.9) 82 (44.1)
Cardiomyopathy, n (%) 193 141 (73.1) 57 (29.5) 6 (3.1) 46 (23.8) 84 (43.5)
Takotsubo cardiomyopathy, n (%) 34 22 (64.7) 8 (23.5) 0 (0.0) 12 (35.3) 14 (41.2)
Infectious endocarditis, n (%) 16 12 (75.0) 6 (37.5) 1 (6.3) 3 (18.8) 6 (37.5)
*p < 0.001 for in-hospital death after weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) vs. ischemic heart disease
Table 4 In-hospital mortality among patients in the cardiogenic shock group, who had or had not had cardiac arrest
Patients who had not
had cardiac arrest
Deaths among patients who
had not had cardiac arrest
Patients who had
had cardiac arrest
Deaths among patients who
had had cardiac arrest
All, n (%)* 2471 1742 (70.5) 2187 1687 (77.1)
Ischemic heart disease, n (%) 803 618 (77.0) 1165 938 (80.5)
Heart failure, n (%)** 922 598 (64.9) 699 501 (71.7)
Valvular disease, n (%) 515 391 (75.9) 125 102 (81.6)
Myocarditis, n (%) 122 67 (54.9) 64 39 (60.9)
Cardiomyopathy, n (%)** 77 47 (61.0) 116 94 (81.0)
Takotsubo cardiomyopathy, n (%) 19 12 (63.2) 15 10 (66.7)
Infectious endocarditis, n (%) 13 9 (69.2) 3 3 (100.0)
*p < 0.001 for mortality among patients who had not had vs. those who had had cardiac arrest
**p < 0.05 for mortality among patients who had not had vs. those who had had cardiac arrest
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Furthermore, for some patients weaned from VA-
ECMO, further treatment may have been discontinued
because of their unfavorable brain condition.
In the cardiogenic shock group, the proportion of in-
hospital deaths under VA-ECMO was smaller than that
after weaning from VA-ECMO, in contrast with the
other groups. This finding may suggest that patients
with cardiogenic shock were more likely to have brain
damage than other groups of patients, resulting in a
lower survival rate. Only two patients received implant-
ation of a left ventricular assistance device. Implantation
of a left ventricular assistance device has only been ap-
proved as a bridge to transplantation since 2011. How-
ever, switching from VA-ECMO to a left ventricular
assistance device is not popular, because of the severe
shortage of cardiac donors in Japan [24].
In-hospital mortality was lower in patients who had
not had cardiac arrest than in those who had had cardiac
arrest. This finding indicates that cardiac arrest may also
be a predictor of VA-ECMO outcome.
In-hospital mortality was higher in older patients and
in patients with high or low BMI. This indicates that
successful outcomes for VA-ECMO in the cardiogenic
group were associated with younger age and appropriate
BMI. This finding could suggest that age and BMI are
predictors of VA-ECMO outcome. Hospital volume was
not significantly associated with in-hospital mortality.
High-volume hospitals may treat severely ill patients on
VA-ECMO more than low-volume hospitals because of
differences in the criteria for implementing VA-ECMO.
Use of IABP was associated with lower mortality. It is rec-
ognized that VA-ECMO increases cardiac afterload due to
its reversed vascular flow. Consequently, VA-ECMO re-
duces cardiac output and causes left ventricular distension
[25]. As IABP reduces afterload and increases coronary
blood flow [26], it may have reduced mortality by increas-
ing cardiac output and decompressing the left ventricle.
There are some limitations in this study. This study
was retrospective and was based on data from an admin-
istrative database, which did not include complete data
on physiology, severity of illness, the patient’s physical
condition, or duration of time between cardiac arrest
Table 5 In-hospital mortality in patients undergoing VA-ECMO
for cardiogenic shock
Patients, n Deaths, n (%) P value
Total 4658 3429 (73.6)
Age, years <0.001
19–39 271 170 (62.7)
40–59 1079 738 (68.4)
60–79 2741 2058 (75.1)
≥ 80 567 463 (81.7)
Sex 0.775
Male 3399 2506 (73.7)
Female 1259 923 (73.3)
Hospital volume per year 0.071
0–9 1671 1263 (75.6)
10–19 1554 1123 (72.3)
≥ 20 1433 1043 (72.8)
Body mass index, kg/m2 <0.001
< 18.5 406 295 (72.7)
18.5–24.9 2223 1521 (68.4)
≥ 25.0 1085 772 (71.2)
Missing 944 841 (89.1)
Etiology <0.001
Ischemic heart disease 1968 1556 (79.1)
Heart failure 1621 1099 (67.8)
Valvular disease 640 493 (77.0)
Myocarditis 186 106 (57.0)
Cardiomyopathy 193 141 (73.1)
Takotsubo cardiomyopathy 34 22 (64.7)
Infectious endocarditis 16 12 (75.0)
Cardiac arrest <0.001
No 2471 1742 (70.5)
Yes 2187 1687 (77.1)
Chronic renal failure 0.464
No 4139 3040 (73.4)
Yes 519 389 (75.0)
Liver failure 0.974
No 4594 3382 (73.6)
Yes 64 47 (73.4)
Central nervous system dysfunction 0.527
No 4605 3392 (73.7)
Yes 53 37 (69.8)
Duration of intubation prior
to VA-ECMO, days
<0.001
0 2576 2007 (77.9)
1 33 23 (69.7)
≥ 2 115 66 (57.4)
Table 5 In-hospital mortality in patients undergoing VA-ECMO
for cardiogenic shock (Continued)
Missing 1934 1333 (68.9)
Use of intra-aortic balloon pumping <0.001
No 1828 1438 (78.7)
Yes 2830 1991 (70.4)
Use of continuous renal replacement therapy <0.001
No 2893 2058 (71.1)
Yes 1765 1371 (77.7)
VA-ECMO venoarterial extracorporeal membrane oxygenation
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and initiation of VA-ECMO. Generally, in retrospective
observational studies using administrative data, recorded
diagnoses are less well-validated than those in planned
prospective surveys. Severe organ dysfunction may have
been more likely to be recorded than mild-to-moderate
dysfunction. The lack of a control group precluded any
conclusion as to whether there was an association be-
tween use of VA-ECMO and mortality. Because of the
way that data were recorded, we were also not able to
differentiate patients who were in cardiac arrest before
ECMO was initiated from those in whom ECMO was
established for ongoing cardiac arrest during cardiopul-
monary resuscitation.
Conclusions
This study was based on data from a nationwide
database in Japan to determine mortality rates in pa-
tients who received VA-ECMO. Mortality rates were
high, especially in patients with cardiogenic shock
and in patients who had cardiac arrest. Weaning from
VA-ECMO did not necessarily result in survival. The
present study provides information about the current
status of VA-ECMO use in Japan; further studies are
needed to investigate the effects of VA-ECMO.
Key messages
 In-hospital mortality was 72.5 % in 5263 patients
receiving VA-ECMO
 More than 50 % of patients weaned from VA-ECMO
died in hospital
 Age, BMI and cardiac arrest were predictors of
mortality after VA-ECMO
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for analysis of in-hospital mortality in patients undergoing
VA-ECMO for cardiogenic shock






40–59 1.08 0.79 1.47 0.65
60–79 1.64 1.23 2.17 0.001
≥ 80 2.61 1.81 3.77 <0.001
Sex
Male Reference
Female 0.96 0.82 1.12 0.61
Hospital volume per year
0–9 Reference
10–19 0.83 0.68 1.01 0.07
≥ 20 0.80 0.63 1.02 0.07
Body mass index, kg/m2
< 18.5 1.28 1.01 1.62 0.04
18.5–24.9 Reference
≥ 25.0 1.24 1.04 1.47 0.02
Etiology
Ischemic heart disease Reference
Heart failure 0.55 0.46 0.65 <0.001
Valvular disease 0.85 0.66 1.10 0.22
Myocarditis 0.42 0.31 0.57 <0.001
Cardiomyopathy 0.75 0.51 1.08 0.12
Takotsubo cardiomyopathy 0.58 0.27 1.21 0.14
Infectious endocarditis 0.69 0.21 2.28 0.55
Cardiac arrest
No Reference
Yes 1.52 1.28 1.82 <0.001
Chronic renal failure
No Reference
Yes 0.90 0.69 1.16 0.40
Liver failure pre-ECMO
No Reference




Yes 0.87 0.45 1.70 0.68
Duration of intubation prior
to VA-ECMO, days
0 Reference
1 1.03 0.44 2.39 0.94
≥ 2 0.47 0.32 0.70 <0.001
Table 6 Multivariable logistic regression with multiple imputation
for analysis of in-hospital mortality in patients undergoing
VA-ECMO for cardiogenic shock (Continued)
Use of intra-aortic balloon pumping
No Reference
Yes 0.58 0.49 0.68 <0.001
Use of continuous renal replacement
therapy
No Reference
Yes 1.95 1.63 2.33 <0.001
VA-ECMO venoarterial extracorporeal membrane oxygenation
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